Charles Zhu
Stock Analyst at LifeSci Capital
(4.87)
# 326
Out of 4,504 analysts
289
Total ratings
64.5%
Success rate
26.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines | Maintained: Buy | $263 | $186.88 | +40.73% | 26 | Jul 11, 2026 | |
| IMNM Immunome | Maintained: Buy | $40 | $23.35 | +71.31% | 18 | Jul 11, 2026 | |
| MOLN Molecular Partners AG | Maintained: Buy | $12 | $4.02 | +198.22% | 19 | Jul 11, 2026 | |
| PBLS Parabilis Medicines | Initiated Coverage: Buy | $42 | $30.57 | +37.39% | 1 | Jul 6, 2026 | |
| ZYME Zymeworks | Maintained: Buy | $34 | $25.88 | +31.38% | 27 | Jun 29, 2026 | |
| KURA Kura Oncology | Maintained: Buy | $28 | $11.45 | +144.54% | 32 | Jun 15, 2026 | |
| IDYA IDEAYA Biosciences | Maintained: Buy | $62 | $36.99 | +67.61% | 50 | Jun 15, 2026 | |
| CNTX Context Therapeutics | Maintained: Buy | $6 | $0.6529 | +818.98% | 7 | Jun 15, 2026 | |
| NUVL Nuvalent | Downgraded: Hold | $124 | $123.90 | +0.08% | 26 | Jun 13, 2026 | |
| RCUS Arcus Biosciences | Initiated Coverage: Buy | $46 | $28.92 | +59.06% | 1 | Jun 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $54 | $29.73 | +81.63% | 4 | May 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $26 | $4.32 | +501.85% | 19 | May 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 | $2.33 | +157.51% | 12 | May 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $3.94 | +103.05% | 8 | May 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $22 → $28 | $17.34 | +61.48% | 10 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $22 | $6.52 | n/a | 1 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $14 | $31.06 | n/a | 3 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 → $20 | $4.33 | n/a | 6 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $26 | $38.87 | n/a | 4 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $45 → $39 | $15.85 | n/a | 4 | May 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $0.76 | n/a | 3 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $39.63 | n/a | 3 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $30 → $20 | $1.24 | n/a | 4 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $2.00 | $0.365 | n/a | 1 | Nov 29, 2022 |
Revolution Medicines
Jul 11, 2026
Maintained: Buy
Price Target: $263
Current: $186.88
Upside: +40.73%
Immunome
Jul 11, 2026
Maintained: Buy
Price Target: $40
Current: $23.35
Upside: +71.31%
Molecular Partners AG
Jul 11, 2026
Maintained: Buy
Price Target: $12
Current: $4.02
Upside: +198.22%
Parabilis Medicines
Jul 6, 2026
Initiated Coverage: Buy
Price Target: $42
Current: $30.57
Upside: +37.39%
Zymeworks
Jun 29, 2026
Maintained: Buy
Price Target: $34
Current: $25.88
Upside: +31.38%
Kura Oncology
Jun 15, 2026
Maintained: Buy
Price Target: $28
Current: $11.45
Upside: +144.54%
IDEAYA Biosciences
Jun 15, 2026
Maintained: Buy
Price Target: $62
Current: $36.99
Upside: +67.61%
Context Therapeutics
Jun 15, 2026
Maintained: Buy
Price Target: $6
Current: $0.6529
Upside: +818.98%
Nuvalent
Jun 13, 2026
Downgraded: Hold
Price Target: $124
Current: $123.90
Upside: +0.08%
Arcus Biosciences
Jun 6, 2026
Initiated Coverage: Buy
Price Target: $46
Current: $28.92
Upside: +59.06%
May 30, 2026
Maintained: Buy
Price Target: $54
Current: $29.73
Upside: +81.63%
May 20, 2026
Maintained: Buy
Price Target: $26
Current: $4.32
Upside: +501.85%
May 9, 2026
Maintained: Buy
Price Target: $6
Current: $2.33
Upside: +157.51%
May 2, 2026
Reiterated: Buy
Price Target: $8
Current: $3.94
Upside: +103.05%
Apr 30, 2026
Maintained: Buy
Price Target: $22 → $28
Current: $17.34
Upside: +61.48%
Jun 18, 2025
Initiated Coverage: Buy
Price Target: $22
Current: $6.52
Upside: n/a
May 24, 2024
Maintained: Buy
Price Target: $14
Current: $31.06
Upside: n/a
Jan 2, 2024
Maintained: Buy
Price Target: $12 → $20
Current: $4.33
Upside: n/a
Jun 13, 2023
Reiterated: Buy
Price Target: $26
Current: $38.87
Upside: n/a
May 9, 2023
Maintained: Buy
Price Target: $45 → $39
Current: $15.85
Upside: n/a
Mar 17, 2023
Maintained: Buy
Price Target: $5
Current: $0.76
Upside: n/a
Jan 3, 2023
Maintained: Hold
Price Target: n/a
Current: $39.63
Upside: n/a
Jan 3, 2023
Maintained: Buy
Price Target: $30 → $20
Current: $1.24
Upside: n/a
Nov 29, 2022
Initiated Coverage: Buy
Price Target: $2.00
Current: $0.365
Upside: n/a